Observational Study
Copyright ©The Author(s) 2017.
World J Virol. Nov 12, 2017; 6(4): 59-72
Published online Nov 12, 2017. doi: 10.5501/wjv.v6.i4.59
Table 3 SVR12 rates for 508 patients who initiated therapy with simeprevir- and/or sofosbuvir-based treatment regimens, calculated on an intention-to-treat basis, with imputed data on 14 patients
SVR12 rates
SVR/total (%)95%CI, %
All treatments372/508 (73)69-77
SMV/SOF ± RBV153/178 (86)80-91
“COSMOS-like" cohort117/130 (90)83-94
SOF/RBV144/234 (62)55-68
145/102 (44)34-54
257/69 (83)71-90
335/52 (67)53-79
47/11 (64)32-88
SOF/PEG/RBV75/96 (78)68-86

  • Citation: Bichoupan K, Tandon N, Crismale JF, Hartman J, Del Bello D, Patel N, Chekuri S, Harty A, Ng M, Sigel KM, Bansal MB, Grewal P, Chang CY, Leong J, Im GY, Liu LU, Odin JA, Bach N, Friedman SL, Schiano TD, Perumalswami PV, Dieterich DT, Branch AD. Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World J Virol 2017; 6(4): 59-72
  • URL: https://www.wjgnet.com/2220-3249/full/v6/i4/59.htm
  • DOI: https://dx.doi.org/10.5501/wjv.v6.i4.59